NO20053903D0 - Nukleotidlipidesterderivater. - Google Patents

Nukleotidlipidesterderivater.

Info

Publication number
NO20053903D0
NO20053903D0 NO20053903A NO20053903A NO20053903D0 NO 20053903 D0 NO20053903 D0 NO 20053903D0 NO 20053903 A NO20053903 A NO 20053903A NO 20053903 A NO20053903 A NO 20053903A NO 20053903 D0 NO20053903 D0 NO 20053903D0
Authority
NO
Norway
Prior art keywords
nukleotidlipidesterderivater
lipidesters
tumors
halogenated
subject
Prior art date
Application number
NO20053903A
Other languages
English (en)
Other versions
NO20053903L (no
Inventor
Dieter Herrmann
Brigitte Heckl-Ostreicher
Christoph Mueller
Christian Lutz
Robert Voigt
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Publication of NO20053903D0 publication Critical patent/NO20053903D0/no
Publication of NO20053903L publication Critical patent/NO20053903L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
NO20053903A 2003-03-19 2005-08-22 Nukleotidlipidesterderivater. NO20053903L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45600303P 2003-03-19 2003-03-19
EP03006059A EP1460082A1 (en) 2003-03-19 2003-03-19 Phospholipid esters of clofarabine derivatives
PCT/EP2004/002810 WO2004083155A2 (en) 2003-03-19 2004-03-18 Nucleotide lipid ester derivatives

Publications (2)

Publication Number Publication Date
NO20053903D0 true NO20053903D0 (no) 2005-08-22
NO20053903L NO20053903L (no) 2005-12-19

Family

ID=33031244

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053903A NO20053903L (no) 2003-03-19 2005-08-22 Nukleotidlipidesterderivater.

Country Status (21)

Country Link
US (1) US7419965B2 (no)
EP (2) EP1460082A1 (no)
JP (1) JP2006520359A (no)
KR (1) KR20050109939A (no)
CN (1) CN100369926C (no)
AT (1) ATE328000T1 (no)
AU (1) AU2004222163A1 (no)
CA (1) CA2519434A1 (no)
CY (1) CY1105572T1 (no)
DE (1) DE602004001047T2 (no)
DK (1) DK1606233T3 (no)
ES (1) ES2265636T3 (no)
MX (1) MXPA05008817A (no)
NO (1) NO20053903L (no)
NZ (1) NZ542011A (no)
PL (1) PL1606233T3 (no)
PT (1) PT1606233E (no)
RU (1) RU2347786C2 (no)
SI (1) SI1606233T1 (no)
WO (1) WO2004083155A2 (no)
ZA (1) ZA200507541B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070938A1 (en) 2007-12-13 2009-06-17 Heidelberg Pharma AG Clofarabine dietherphospholipid derivatives
CN102079766A (zh) * 2009-11-29 2011-06-01 海南中化联合制药工业股份有限公司 一种单磷酸阿糖腺苷的制备方法
CN101709073B (zh) * 2009-12-01 2013-01-23 北京大学 核苷酸磷脂分子及脂质体及其制备方法和应用
CN103232510B (zh) * 2012-11-23 2015-12-23 北京大学 5’-氨基-2’,5’-双脱氧核苷酸磷脂分子及其制备方法和应用
US9771385B2 (en) * 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
KR102371969B1 (ko) 2016-12-23 2022-03-08 주식회사 엘지에너지솔루션 배터리 모듈
JP7465416B2 (ja) 2018-06-26 2024-04-11 ティーエスアールエル インコーポレイテッド 代謝安定性プロドラッグ
WO2024059754A1 (en) * 2022-09-14 2024-03-21 Quantapore, Inc. Polythiolated linkers for stable nanoparticle suspensions and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4751221A (en) 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
JPS6383094A (ja) * 1986-09-27 1988-04-13 Toyo Jozo Co Ltd エ−テル型ヌクレオシド−リン脂質複合体
DE4026265A1 (de) 1990-08-20 1992-02-27 Boehringer Mannheim Gmbh Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
DE4321978A1 (de) * 1993-07-01 1995-01-12 Boehringer Mannheim Gmbh Liponucleotide von Desoxynucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
AU711367B2 (en) * 1994-11-12 1999-10-14 Heidelberg Pharma Holding Gmbh Lipid-splitting enzyme
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells

Also Published As

Publication number Publication date
WO2004083155A2 (en) 2004-09-30
DK1606233T3 (da) 2006-09-18
ATE328000T1 (de) 2006-06-15
CA2519434A1 (en) 2004-09-30
PT1606233E (pt) 2006-09-29
KR20050109939A (ko) 2005-11-22
AU2004222163A1 (en) 2004-09-30
ZA200507541B (en) 2006-05-31
EP1460082A1 (en) 2004-09-22
RU2347786C2 (ru) 2009-02-27
PL1606233T3 (pl) 2006-10-31
DE602004001047T2 (de) 2007-04-19
WO2004083155A3 (en) 2005-03-31
CY1105572T1 (el) 2010-07-28
NZ542011A (en) 2008-02-29
NO20053903L (no) 2005-12-19
US20060293514A1 (en) 2006-12-28
MXPA05008817A (es) 2005-10-18
ES2265636T3 (es) 2007-02-16
DE602004001047D1 (de) 2006-07-06
JP2006520359A (ja) 2006-09-07
SI1606233T1 (sl) 2006-10-31
CN1771253A (zh) 2006-05-10
EP1606233B1 (en) 2006-05-31
US7419965B2 (en) 2008-09-02
EP1606233A2 (en) 2005-12-21
RU2005130992A (ru) 2006-04-10
CN100369926C (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
TW200612918A (en) Lonidamine analogs
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
BR0315689A (pt) Alvo para terapia de dano cognitivo
AU2003237367A8 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ATE461217T1 (de) Glp-1-verbindungen
NO20053903D0 (no) Nukleotidlipidesterderivater.
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
CY1114443T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
ATE305932T1 (de) Rapanycin29-enole
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
BRPI0509660A (pt) compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
SE9904377D0 (sv) Pharmaceutical combinations
SE0302304D0 (sv) Novel compounds
DE60223576D1 (de) Hautbehandlungszusammensetzung
SE0301650D0 (sv) Novel compounds
ATE399523T1 (de) Haarbehandlungszusammensetzung
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
DK1496918T3 (da) Anvendelse af natriummetaarsenit til behandling af tumorer
ATE391489T1 (de) Haarbehandlungszusammensetzungen
ATE347883T1 (de) Verwendung von n-(2-aryl-propionyl)-sulfonamiden zur behandlung von rückenmarkverletzungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application